Evidence map›Paper›PMID 40791395›Full record

ArticlebioRxiv : the preprint server for biology2025

The Human Chk1 Inhibitor CHIR-124 Shows Multistage Activity Against

Kathryn J Wicht, John G Woodland, Larnelle F Garnie, Henrico Langeveld, Dale Taylor, Luiz C Godoy, Charisse Flerida A Pasaje, Mariana Laureano de Souza, Jair L Siqueira-Neto, Sonja Ghidelli-Disse and 18 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors.

Kathryn J WichtHolistic Drug Discovery and Development (H3D) Centre, University of Cape Town, Rondebosch 7701, South Africa.ORCID 0000-0001-6145-9956
John G WoodlandHolistic Drug Discovery and Development (H3D) Centre, University of Cape Town, Rondebosch 7701, South Africa.
Larnelle F GarnieDepartment of Chemistry, University of Cape Town, Rondebosch, 7701, South Africa.
Henrico LangeveldDepartment of Biochemistry, Genetics and Microbiology, Institute for Sustainable Malaria Control, University of Pretoria, Hatfield 0028, South Africa.
Dale TaylorHolistic Drug Discovery and Development (H3D) Centre, University of Cape Town, Rondebosch 7701, South Africa.
Luiz C GodoyDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Charisse Flerida A PasajeDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Mariana Laureano de SouzaDepartment of Pediatrics and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA, USA.
Jair L Siqueira-NetoDepartment of Pediatrics and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA, USA.
Sonja Ghidelli-DisseCellzome GmbH, a GSK Company, Heidelberg, Germany.
Maria Jose Lafuente-MonasterioGlaxoSmithKline, Tres Cantos Medicines Development Campus, Madrid, Spain.
Francisco-Javier GamoGlaxoSmithKline, Tres Cantos Medicines Development Campus, Madrid, Spain.
Dina CoertzenDepartment of Biochemistry, Genetics and Microbiology, Institute for Sustainable Malaria Control, University of Pretoria, Hatfield 0028, South Africa.
Janette ReaderDepartment of Biochemistry, Genetics and Microbiology, Institute for Sustainable Malaria Control, University of Pretoria, Hatfield 0028, South Africa.
Mariëtte van der WattDepartment of Biochemistry, Genetics and Microbiology, Institute for Sustainable Malaria Control, University of Pretoria, Hatfield 0028, South Africa.
Jessica L BridgfordDepartment of Microbiology and Immunology, and Center for Malaria Therapeutics and Antimicrobial Resistance, Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
Gareth GirlingWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.
Rachael CoyleWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.
Christian ScheurerDepartment of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, 4123 Allschwil, Switzerland.
Sergio WittlinDepartment of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, 4123 Allschwil, Switzerland.
Marcus C S LeeWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.
Till S VossDepartment of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, 4123 Allschwil, Switzerland.
Elizabeth A WinzelerDepartment of Pediatrics and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA, USA.
David A FidockDepartment of Microbiology and Immunology, and Center for Malaria Therapeutics and Antimicrobial Resistance, Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
Jacquin C NilesDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Lyn-Marié BirkholtzDepartment of Biochemistry, Genetics and Microbiology, Institute for Sustainable Malaria Control, University of Pretoria, Hatfield 0028, South Africa.
Lauren B CoulsonHolistic Drug Discovery and Development (H3D) Centre, University of Cape Town, Rondebosch 7701, South Africa.
Kelly ChibaleHolistic Drug Discovery and Development (H3D) Centre, University of Cape Town, Rondebosch 7701, South Africa.ORCID 0000-0002-1327-4727

Funding

Defining the complex genetic basis of Plasmodium falciparum resistance to artemisinin and quinine and identifying resistance-refractory therapeuticsR01AI185559 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI David A Fidock · 2024 to 2026
$1.9M
Repurposing kinase inhibitor chemotypes as antimalarialsR01AI152092 · NIAID · UNIVERSITY OF CAPE TOWN · PI CHIBALE, KELLY, FERRINS, LORI · 2020 to 2024
$1.6M
New tools for antimalarial target identificationR01AI143521 · NIAID · UNIVERSITY OF CAPE TOWN · PI WICHT, KATHRYN JEAN · 2019 to 2023
$709k
NIAID NIH HHS R01 AI143521NIAID NIH HHS R01 AI152092NIAID NIH HHS R01 AI185559
6 · The paper itself

Abstract

The high burden of malaria and growing resistance to frontline antimalarials demand new drugs with reduced propensities for generating resistance. An attractive approach to identifying chemical hits as starting points for antimalarial drug discovery involves the repositioning and chemical optimization of compounds used in other disease areas that are active against the human malaria parasite

Indexed as

Antiprotozoal agentsbiological activityhemozoinkinasePlasmodium

Identifiers

PMID40791395
PMCPMC12338603

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.